Medication for Diarrhea

Marion Debus

Last update: 12.06.2019

  • For diarrhea:
    Birkenkohle comp. caps. WELEDA (also available as Carbo Betulae comp. tabs. WELEDA), 2 per bowel movement, or 3 x daily up to hourly
    or
    Bolus alba comp. powder WALA, 1–3 tsp. daily, each in 200 ml liquid 

  • For diarrhea and vomiting:
    Bolus alba comp. powder WALA, 1 saltsp. (~1/4 tsp.) hourly 

  • In situations of damage to the small intestine mucosa caused by chemotherapy or radiation therapy:
    Digestodoron® WELEDA, chew 2 tabs. at the beginning of each meal 3x/d, or 15 drops 4x/d
    or
    in addition, to stimulate renal and hepatic detoxification function while undergoing chemotherapy:
    Aquilinum comp. pillules WALA, 7–10 pillules 3x/d or 1 amp. per os 1x/d

  • In case of mucous membrane damage as a result of radiation therapy:
    Stibium arsenicosum D6 trit. WELEDA, 1 saltsp. (~1/4 tsp.) 3x/d
    or,
    with particularly mucousy diarrhea:
    Geum urbanum D1 WELEDA, 10 drops 3–6x/d

  • For Enterocolitis with mucousy diarrhea and high fluid loss:
    Quartz powder 50% WELEDA, take ¼ tsp. with a little liquid 5x/d

  • For unrelenting diarrhea in GvHD after bone marrow transplantation:
    Luvos Healing Earth gastro balance (also available as Luvos-Heilerde magenfein), 1 tsp. 3x/d

  • Diarrhea during radiation of the rectum as part of (neo)adjuvant chemoradiotherapy for rectal cancer. In the last third of therapy, local irritations and diarrhea can usually be expected.
    Local: Mercurialis ointment WALA and Mercurialis comp. supp. WALA 
    or,
    Bolus alba comp. powder WALA
    Stibium arsenicosum D6 trit. WELEDA, 1 saltsp. (~1/4 tsp.) 3x/d
    Geum urbanum D1 WELEDA, 10 drops 3–6x/d

Research news

Phase IV trial: Kalium phosphoricum comp. versus placebo in irritability and nervousness 
In a new clinical study, Kalium phosphoricum comp. (KPC) versus placebo was tested in 77 patients per group. In a post-hoc analysis of intra-individual differences after 6 weeks treatment, a significant advantage of KPC vs. placebo was shown for characteristic symptoms of nervous exhaustion and nervousness (p = 0.020, p = 0.045 respectively). In both groups six adverse events (AE) were assessed as causally related to treatment (severity mild or moderate). No AE resulted in discontinuation in treatment. KPC could therefore be a beneficial treatment option for symptomatic relief of neurasthenia. The study has been published open access in Current Medical Research and Opinion
https://doi.org/10.1080/03007995.2023.2291169.


Further information on Anthroposophic Medicine